Lisette Lopez-Rose expected joy after childbirth. She instead suffered panic attacks and deep sadness. She feared telling her obstetrician. She worried they might take her baby away. At six months postpartum she found an online group of women with similar struggles. She then opened up to her primary care doctor. Two months after starting medication, she began to feel better. She now helps other new mothers find online support.
How common is postpartum depression?
About one in eight women in the United States experience postpartum depression. It is one of the most common complications after childbirth. Symptoms usually begin within the first few weeks after delivery. The condition often follows the sudden drop in estrogen and progesterone after pregnancy.
New diagnostic approach: a blood test
A San Diego startup has developed a blood test called myLuma. The company says the test predicts a pregnant woman’s risk of postpartum depression with more than 80 percent accuracy. myLuma uses biomarkers in the blood to estimate risk. If a woman learns she is at higher risk, she can plan preventive steps. These steps may include early medication or arranging extra support after birth.
Why a blood test matters
Experts say a biological test could reduce stigma. A blood result makes the condition easier for many people to understand. That could help more women accept and seek treatment.
Scientific basis: epigenetic markers
Researchers found two genes linked to hormone sensitivity: HP1BP3 and TTC9B. Changes in methylation of these genes appeared in blood samples of women who later developed postpartum depression. Studies showed the methylation pattern could be detected during pregnancy. In research with hundreds of women, the pattern predicted postpartum depression in roughly eight out of ten cases. These findings form the basis of the myLuma test.
Additional biomarkers improve accuracy
The myLuma test also includes other biomarkers. Combining markers increases predictive power. The company plans to offer the test in some doctors’ offices starting in January 2026 in Florida, Texas and California. The test is not yet FDA-approved. Doctors can use certain lab-developed tests to inform clinical decisions before full approval.
Steroids and brain chemistry
Researchers are also studying neuroactive steroids produced from progesterone. One of these chemicals, allopregnanolone, rises in pregnancy and falls after birth. It acts on the GABA-A receptor and has calming effects. Other related steroids, like pregnanolone and isoallopregnanolone, influence stress and mood. A 2025 study found that imbalances in these chemicals during pregnancy were linked to higher postpartum depression risk.
Treatments: from drugs to support networks
The first drug approved specifically for postpartum depression was cleared by regulators in 2019. That drug is a derivative of progesterone and represented a new treatment approach. A synthetic form of allopregnanolone, called brexanolone, is used to treat some cases. Medication, therapy and social support all play important roles. Early identification of risk allows clinicians and families to plan care proactively.
What this means for pregnant women and clinicians
Simple screening and new lab tests could change care for new mothers. Predictive tests may let doctors offer prevention to those at high risk. They may also normalize treatment by framing postpartum depression as a biological condition. Continued research is needed to expand markers and improve access to testing and treatment.
Postpartum depression is common and treatable. New biomarker tests and targeted treatments are improving diagnosis and care. Women who feel persistent sadness or anxiety after childbirth should seek help from a health professional. Early support and treatment can lead to recovery.
Related topics
